Similarly, PTH, the only approved anabolic drug for the treatment of osteoporosis together with the anti-sclerostin antibody Romosozumab (Lindsay et al., 2016), promotes bone formation, but also leads to increased bone resorption as a secondary effect (Silva et al., 2011). This evidence concerns the gene PTH and osteoporosis.